SynAct Pharma AB (OSTO:SYNACT) Cyclically Adjusted Book per Share: kr2.78 (As of Mar. 2026)


OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
19 GF Score
Price kr18.92
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB Cyclically Adjusted Book per Share?

SynAct Pharma AB OSTO:SYNACT +2.16% 19 Cyclically Adjusted Book per Share is kr2.78 as of Mar. 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

SynAct Pharma AB's adjusted book value per share for the three months ended in Mar. 2026 was kr3.460. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr2.78 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-04), SynAct Pharma AB's current stock price is kr18.92. SynAct Pharma AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was kr2.78. SynAct Pharma AB's Cyclically Adjusted PB Ratio of today is 6.81.

During the past 10 years, the highest Cyclically Adjusted PB Ratio of SynAct Pharma AB was 5.56. The lowest was 0.00. And the median was 0.00.


SynAct Pharma AB  (OSTO:SYNACT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

SynAct Pharma AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=18.92/2.78
=6.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 10 years, the highest Cyclically Adjusted PB Ratio of SynAct Pharma AB was 5.56. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


SynAct Pharma AB Cyclically Adjusted Book per Share Related Terms


SynAct Pharma AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB Cyclically Adjusted Book per Share Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SynAct Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.78

OSTO:SYNACT vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, SynAct Pharma AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynAct Pharma AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's Cyclically Adjusted PB Ratio falls into.


OSTO:SYNACT
19GF Score
SynAct Pharma AB OSTO:SYNACT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SynAct Pharma AB's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.46/133.5600*133.5600
=3.460

Current CPI (Mar. 2026) = 133.5600.

SynAct Pharma AB Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 101.019 0.000
201609 2.728 101.138 3.603
201612 2.091 102.022 2.737
201703 1.900 102.022 2.487
201706 1.586 102.752 2.062
201709 1.425 103.279 1.843
201712 0.984 103.793 1.266
201803 0.783 103.962 1.006
201806 1.567 104.875 1.996
201809 1.119 105.679 1.414
201812 0.641 105.912 0.808
201903 0.431 105.886 0.544
201906 -0.042 106.742 -0.053
201909 -0.259 107.214 -0.323
201912 0.819 107.766 1.015
202003 0.447 106.563 0.560
202006 0.183 107.498 0.227
202009 1.083 107.635 1.344
202012 0.641 108.296 0.791
202103 2.985 108.360 3.679
202106 2.485 108.928 3.047
202109 1.791 110.338 2.168
202112 0.792 112.486 0.940
202203 0.029 114.825 0.034
202206 3.586 118.384 4.046
202209 2.797 122.296 3.055
202212 4.229 126.365 4.470
202303 8.370 127.042 8.799
202306 7.521 129.407 7.762
202309 6.537 130.224 6.704
202312 4.908 131.912 4.969
202403 4.243 132.205 4.286
202406 4.487 132.716 4.516
202409 4.059 132.304 4.098
202412 4.607 132.987 4.627
202503 3.696 132.825 3.716
202506 3.938 133.699 3.934
202509 3.653 133.480 3.655
202512 3.193 133.390 3.197
202603 3.460 133.560 3.460

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of kr2.78 mean?
SynAct Pharma AB (OSTO:SYNACT) has a Cyclically Adjusted Book per Share of kr2.78 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on SynAct Pharma AB and its competitors.
Is SynAct Pharma AB's Cyclically Adjusted Book per Share too high?
SynAct Pharma AB's current Cyclically Adjusted Book per Share is kr2.78. Overall, SynAct Pharma AB has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
SynAct Pharma AB's Cyclically Adjusted Book per Share of kr2.78 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on SynAct Pharma AB and its competitors. SynAct Pharma AB's current Cyclically Adjusted Book per Share is kr2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current Cyclically Adjusted Book per Share of kr2.78. The current Cyclically Adjusted Book per Share is kr2.78. SynAct Pharma AB's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current Cyclically Adjusted Book per Share is kr2.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
19GF Score

Get the complete analysis for OSTO:SYNACT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.92
Price